A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'Does tranexamic acid stop haemoptysis'? Altogether 49 papers were found using the reported search strategy, of which 13 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. This consisted of one systematic review including a meta-analysis of two double-blind randomized controlled trials (RCTs), the two RCTs, one cohort study, two case-series and seven case reports. Main outcomes included bleeding time, bleeding volume and occurrence of thromboembolic complications after start of treatment. Based on results from the meta-analysis, no difference in remission of bleeding within 1 week was found between tranexamic acid (TA) and placebo groups (odds ratio 1.56, 95% CI: 0.44-5.46). However, overall bleeding time was significantly shorter for the TA group (weighted mean difference −19.47, 95% CI: −26.90, −12.03 h). In one RCT, TA reduced both the duration and the volume of bleeding compared with patients receiving placebo (both P < 0.0005). However, the other RCT failed to find a difference in bleeding time (P = 0.2). In these studies, no patient suffered from thromboembolic complications. Two case reports, however, describe development of pulmonary embolism during TA treatment. Several case reports on the use of TA for treatment of haemoptysis secondary to cystic fibrosis were found. In general, they suggest that TA may be a useful and well-tolerated medication for the treatment of intractable haemoptysis in this patient group. We conclude that limited research on the use of TA for treatment of haemoptysis exists. As aetiology of haemoptysis as well as length of treatment, dosage and form of TA administration varied between the studies, strong recommendations are difficult to give. Current best evidence, however, indicates that TA may reduce both the duration and volume of bleeding, with low risk of short-term thromboembolic complications, in patients with haemoptysis.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION

In [ patients with haemoptysis] does [administration of tranexamic acid] stop [bleeding]?
CLINICAL SCENARIO
While working in a cardiothoracic surgery unit, you receive a phone call from the emergency unit where they are updating local hospital guidelines on patient management. They are currently reviewing the section on management of haemoptysis and ask you whether you recommend administration of tranexamic acid (TA) as part of the treatment. You admit that you are unsure what to answer and decide to check the literature concerning TA as treatment for haemoptysis.
SEARCH STRATEGY
Medline was searched from 1946 to February week 11 2013 using the OVID interface.
[ Studies were included if TA was used as part of treatment for haemoptysis in humans. The reference list of included articles was then scanned for additional articles of relevance not occurring in the primary search. Also, PubMed was searched using phrases from the primary search.
SEARCH OUTCOME
Forty-six papers were found using the reported search. From these, 10 papers were identified that provided the best evidence to answer the question. Three additional papers, one randomized controlled trial (RCT) and two case reports were found from the extended search. The 13 papers are presented in Table 1 . [3] where 24 patients with haemoptysis secondary to tuberculosis were randomized to receive TA or placebo intravenously for 3 days. According to this study, TA reduced both the duration and the volume of bleeding compared with patients receiving placebo (both P < 0.0005). The other RCT was performed by Tscheikuna et al. [4] where 46 patients with haemoptysis of various underlying aetiologies were randomized to receive TA or placebo orally for 7 days or until haemoptysis resolved. Data from this study alone did, however, not find a difference in bleeding time between the TA and the placebo group (P = 0.2). Bleeding volume was not assessed in this study.
Márquez-Martín et al. [5] studied the effect of endobronchial administration of a TA solution during bronchoscopy in 48 consecutive patients with non-life-threatening haemoptysis. The TA solution was applied directly onto the bleeding lesion or selectively in the bleeding bronchus. Patients were divided into an iatrogenic group (bleeding due to diagnostic bronchoscopy, n = 20) or a noniatrogenic group (spontaneous bronchial bleeding, n = 28). In the iatrogenic group, bleeding successfully stopped in all patients after endobronchial administration of TA. In the non-iatrogenic group, however, only 11 patients (39.2%) were successfully treated. It was found that non-responders more frequently had bronchiectasis (58.3 vs 18.8%, P = 0.039) and less frequently had malignancies (16.7 vs 56.3%, P = 0.040) when compared with responders. The study did not evaluate total blood loss and follow-up time was limited to 3 months. Of 66 patients originally included in the study, 11 (16.6%) had recurrent haemoptysis after 3 months. Recurrence rate did not differ between patients treated with endobronchial TA or not. No patient suffered from thrombotic events.
Solomonov et al. [6] presents a case-series of 6 patients treated with TA for haemoptysis of various aetiologies. TA was instilled through the bronchoscope as a single dose (n = 2) or inhaled up to four times a day lasting days to months (n = 4). In all the 6 patients, haemoptysis resolved within minutes to hours of starting with TA. This study concludes that TA administered via the bronchoscope or through inhalation seems effective in treating haemoptysis from both identifiable and unidentifiable bleeding sites.
Zamani [7] presents a case-series where patients undergoing bronchoscopy were treated with intratumoral injection of TA for control of biopsy-induced bleeding. For both patients, bleeding stopped within minutes of starting treatment, suggesting that this procedure could be performed as a prebiopsy measure to prevent biopsyinduced bleeding.
Devine and Radford [8] present a case report on the successful treatment of haemoptysis in pulmonary atresia with TA.
Several case reports on the use of TA for treatment of haemoptysis secondary to cystic fibrosis (CF) were found [9] [10] [11] [12] [13] . In these reports, TA was given alone, prior to, or in conjunction with bronchial artery embolization (BAE) or pulmonary resection. One study reports the occurrence of acute pulmonary embolism (PE) [13] . The other reports conclude that TA may be a useful and welltolerated medication for the treatment of intractable haemoptysis in patients with CF.
Krivokuca and Lammers [14] presents a case report where a woman, with a history of PE, used TA as treatment for chronic haemoptysis secondary to bronchiectasis. After 6 months she was diagnosed with a new PE. It was concluded that care should be taken when prescribing TA to patients with a history of PE.
CLINICAL BOTTOM LINE
Limited research on the use of TA for treatment of haemoptysis exists. As the aetiology of haemoptysis as well as length of treatment, dosage and form of TA administration varied between the studies, strong recommendations are difficult to give. Current best evidence, however, indicates that TA may reduce both the duration and volume of bleeding, with low risk of short-term thromboembolic complications, in patients with haemoptysis.
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